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Pancreatic ductal adenocarcinomas (PDAC), is a highly aggressive and lethal cancer, which 
has only a 5-year chance of survival. This type of cancer tends to be resistant to normal 
therapies, and thus makes a crucial area for drug design. PDAC grows and spreads around 
the body with incredible speed, giving patients with little hope of survival. Research indicates 
that these cancers create and pump out large amounts of a small protein called S100P, and 
this has been linked to the aggressive progression of disease.  
Our team of computational and synthetic chemists developed a bank of 93 new compounds 
based on the known asthma drug Cromolyn. These computer generated synthetic compounds 
would in theory have the ability to block S100P from binding to its target on the cell surface, a 
receptor known as RAGE. The aim of the project was to find out which of the 93 compounds 
have the optimal structure to prevent S100P from binding RAGE, and therefore stop the 
progression of the cancer.  
Using molecular biology techniques, involving making the human S100P protein in bacteria, 
purifying this protein and then measuring whether the new compounds prevents S100P 
binding to RAGE.  In order to make sure that the results were reliable, each drug was tested 
a total of 9 times at 4 different concentrations (10μM-10nM), and from this assay 18 
compounds were identified that could be further investigated. These candidate drugs were 
then screened to check and see how toxic these drugs are. These assays indicated that the 
compounds weren’t killing the pancreatic cells even over long periods of time (up to a week). 
However, further experiments were conducted to measure how the 18 lead compounds could 
change the way in which pancreatic cells migrate. For this, human pancreatic cancer cells 
(BxPC-3) and human pancreatic cancerous cells (non- S100P expressing) Panc-1 cells were 
grown in 3-D matrix which allows them to grow through and migrate to the other side. This 
represents the way in which cells would migrate and proliferate in a human organs. After 48 
hours of exposure to each of the 18 drugs, 13 of the compounds prevented the cancerous 
BxPC-3 cells from migrating, but not the human Panc-1cells.  
These 13 drugs will next be tested to see if they can prevent the formation of new blood 
vessels in chicken egg membranes. As cancers grow they require a greater blood supply, and 
so any drug that prevents this development will help to slow the growth and lethality of the 
disease. 
The newly synthesised drugs provide us with a greater insight into how we can tackle this 
pernicious and devastating disease. From these structure of these compounds, we will better 
understand how to prevent the rapid migration of the pancreatic cancer, and direct the 
chemists to further develop the drugs so that they will be safely given to man within the next 
few years. Evidence from other laboratories indicate that when you prevent the S100P from 
increasing proliferation and migration of cells, we can also make the cancers more prone to 
normal therapies such as chemotherapy. There are several other types of cancer that are also 
driven by S100P, and any resulting drug would therefore have the potential to stop the 
progression of some types of lung and breast cancers. The results so far indicate that we have 
the potential to have created a new therapy for pancreatic cancer that will be non-toxic to cells, 
prevent migration and thus make pancreatic cancer a treatable disease. 
